Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis (NCT06408259)

🧪 Interventions in This Study

• Ozanimod (DRUG)
• Fingolimod (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (33 Sites)

Showing the first 25 of 33 sites.

• Local Institution - 0114 — Loma Linda, California
• University of California Davis Health — Sacramento, California
• University of South Florida — Tampa, Florida
• Local Institution - 0093 — Chicago, Illinois
• University of Chicago Medical Center — Chicago, Illinois
• University of Louisville, Norton Children's Research Institute — Louisville, Kentucky
• Local Institution - 0131 — New Brunswick, New Jersey
• Local Institution - 0132 — Teaneck, New Jersey
• Local Institution - 0091 — Cincinnati, Ohio
• Local Institution - 0092 — Portland, Oregon
• Local Institution - 0133 — El Paso, Texas
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Royal Children's Hospital — Melbourne, Victoria
• University of Naples Federico II — Naples, Campania
• Ospedale San Raffaele — Milan, Lombardy
• Local Institution - 0081 — Milan, Lombardy
• Neurological Center Of Latium — Rome, Roma
• Local Institution - 0078 — Mexico City, DIF
• Uniwersytecki Szpital Kliniczny w Poznaniu — Poznan, Greater Poland Voivodeship
• 2Ca Braga — Braga,
• Unidade Local de Saúde de Coimbra, E.P.E. — Coimbra,
• Centro Hospitalar de Lisboa Central — Lisbon,
• Local Institution - 0102 — Porto,
• Local Institution - 0134 — Caguas,
• Spitalul Clinic de Copii Doctor Victor Gomoiu — Bucharest, Bucharest

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Sclerosis, Relapsing-Remitting

• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS — Aurora, Colorado
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis — La Jolla, California
• Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Altamonte Springs, Florida
• A Post-Authorization, Long-term Study of Ozanimod Real-world Safety — Bethesda, Maryland
• Efficacy of Diet on Quality of Life in Multiple Sclerosis — Iowa City, Iowa

Explore by condition: All Multiple Sclerosis, Relapsing-Remitting clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.